Biologic and targeted synthetic DMARD safety in inflammatory arthritis: British Society for Rheumatology guideline scope

TL;DR

This paper outlines a new guideline for safely using biologic and synthetic drugs to treat inflammatory arthritis in people of all ages.

Contribution

The guideline includes newer drugs like Janus kinase inhibitors and expands to cover children and young people with inflammatory arthritis.

Findings

The guideline incorporates newer pharmacotherapies such as Janus kinase inhibitors.

It extends recommendations to include children and young people with inflammatory arthritis.

Abstract

This guideline will provide up-to-date and evidence-based recommendations for the safe use of biologic and targeted synthetic DMARDs in individuals with inflammatory arthritis (IA) across the life course. Important updates from the 2019 iteration of this guideline will include the incorporation of newer pharmacotherapies (such as Janus kinase inhibitors) and an extension of the target clinical population to cover children and young people with IA. The guideline will be updated and produced in accordance with the British Society for Rheumatology protocol for developing clinical guidelines, updated 2023.